Next Article in Journal
Inflammation-Related Risk Loci in Genome-Wide Association Studies of Coronary Artery Disease
Next Article in Special Issue
Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype
Previous Article in Journal
Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
Article

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

1
Department of Clinical Pharmacy, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands
2
ILD Center of Excellence, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands
3
Division of Heart and Lungs, Department of Pulmonology, University Medical Centre, 3508 GA Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Alain Calender
Cells 2021, 10(2), 441; https://doi.org/10.3390/cells10020441
Received: 21 January 2021 / Revised: 11 February 2021 / Accepted: 16 February 2021 / Published: 19 February 2021
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade® or Inflectra® to Flixabi® in patients with severe refractory sarcoidosis. This single center retrospective cohort study was performed at St Antonius Hospital Nieuwegein, The Netherlands. All patients diagnosed with severe refractory sarcoidosis receiving Remicade® or Inflectra® switched to Flixabi®. The primary outcome was infliximab discontinuation within 6 months of switching. Secondary endpoints included adverse events and loss of clinical, functional, or inflammatory response. Out of 86 patients who switched to Flixabi®, 79 patients had complete data. None of the 79 patients discontinued infliximab during the first 6 months after switching. Five patients reported an adverse event related to Flixabi® treatment. We found no change from baseline in FVC, FEV1, DLCOc, 6MWT, and infliximab trough levels 26 weeks after switching. An improvement in physical functioning of 7.3 ± 13.4 points (p = 0.002) with RAND/SF36 and in biomarker sIL-2R (−475.58 ± 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade® or biosimilar infliximab Inflectra® to biosimilar infliximab Flixabi® did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission. View Full-Text
Keywords: biosimilar; infliximab; sarcoidosis; TNF-α inhibitor biosimilar; infliximab; sarcoidosis; TNF-α inhibitor
MDPI and ACS Style

Peters, B.J.M.; Bhatoe, A.; Vorselaars, A.D.M.; Veltkamp, M. Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients. Cells 2021, 10, 441. https://doi.org/10.3390/cells10020441

AMA Style

Peters BJM, Bhatoe A, Vorselaars ADM, Veltkamp M. Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients. Cells. 2021; 10(2):441. https://doi.org/10.3390/cells10020441

Chicago/Turabian Style

Peters, Bas J.M., Anish Bhatoe, Adriane D.M. Vorselaars, and Marcel Veltkamp. 2021. "Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients" Cells 10, no. 2: 441. https://doi.org/10.3390/cells10020441

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop